A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma
American Journal of Cancer Research · 2025 · 15 (3) · 876-893
DOI: 10.62347/squf6988 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cancer Research, 2025. Verfasst von Yingchuan Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu 610041, Sichuan, China. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu 610041, Sichuan, China.
Zitieren
APA
Zhu, Y., Song, Y., Jiang, W., Zhang, J., Yin, L., Lin, X., Lu, Y., Tao, D., & Ma, Y. (2025). A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma. American Journal of Cancer Research, 15(3), 876-893. https://doi.org/10.62347/squf6988
Vancouver
Zhu Y, Song Y, Jiang W, Zhang J, Yin L, Lin X, et al. A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma. American Journal of Cancer Research. 2025;15(3):876-893. doi:10.62347/squf6988
BibTeX
@article{Zhu2025,
author = {Zhu, Yingchuan and Song, Yue and Jiang, Wenhao and Zhang, Jingfei and Yin, Lan and Lin, Xinyu and Lu, Yilu and Tao, Dachang and Ma, Yongxin},
title = {A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma},
journal = {American Journal of Cancer Research},
year = {2025},
volume = {15},
number = {3},
pages = {876--893},
doi = {10.62347/squf6988}
}
EUVIMED